Shortcoming of ypStage staging system: Lack of differentiation for preoperative treatment
- PMID: 40080470
- PMCID: PMC11906041
- DOI: 10.1371/journal.pone.0318854
Shortcoming of ypStage staging system: Lack of differentiation for preoperative treatment
Abstract
The eighth edition of the AJCC staging manual initially proposed the ypTNM staging system, which was specifically designed to assess the staging and predict the prognosis of cancer patients undergoing preoperative treatment. Nevertheless, it remains unclear whether this staging system is an accurate predictor of outcomes for cancer patients undergoing different preoperative treatments. The clinical and pathological data of gastric cancer patients who received preoperative treatment and subsequent curved tented gastrostomy were obtained from the Surveillance, Epidemiology, and End Results database. A comparison of survival rates was conducted between patients with the same ypStage staging who received preoperative chemotherapy or chemoradiotherapy, using the Kaplan-Meier method. Additionally, a Cox regression analysis was performed to identify the factors influencing survival following preoperative treatment. A total of 202 patients were included in the study. The results demonstrated a statistically significant difference (p < 0.05) in survival between patients who received preoperative chemoradiotherapy and those who received preoperative chemotherapy in ypStage II or III patients.Cox regression analysis revealed that ypT, ypN and ypStage were associated with OS, but were not independent prognostic factors following gastrectomy. The survival of gastric cancer patients who are classified in the same ypStage stage but who receive disparate preoperative treatments is not analogous. The eighth edition staging system remains in need of further refinement to ensure accurate prediction of prognosis following diverse preoperative therapeutic regimens.
Copyright: © 2025 Du et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
he authors have declared that no competing interests exist.
Figures




Similar articles
-
Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy.Gastric Cancer. 2018 Jan;21(1):74-83. doi: 10.1007/s10120-017-0743-4. Epub 2017 Jun 22. Gastric Cancer. 2018. PMID: 28643144 Free PMC article.
-
Clinical Significance of Residual Lymph Node Metastasis in Predicting Recurrence After Preoperative Chemotherapy and Surgery for Gastric Cancer.Anticancer Res. 2025 Mar;45(3):1205-1214. doi: 10.21873/anticanres.17507. Anticancer Res. 2025. PMID: 40037862
-
ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system.Gastric Cancer. 2018 Nov;21(6):977-987. doi: 10.1007/s10120-018-0830-1. Epub 2018 May 10. Gastric Cancer. 2018. PMID: 29748876
-
ypTNM staging is a potentially useful prognostic stratification tool in patients with advanced gastric cancer after preoperative chemotherapy.Langenbecks Arch Surg. 2023 Mar 31;408(1):133. doi: 10.1007/s00423-023-02872-x. Langenbecks Arch Surg. 2023. PMID: 37000278
-
Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.Dis Esophagus. 2016 Nov;29(8):906-912. doi: 10.1111/dote.12538. Dis Esophagus. 2016. PMID: 27905170 Free PMC article.
References
-
- Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, et al.. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol. 1989;7(9):1318–26. Epub 1989/09/01. doi: 10.1200/JCO.1989.7.9.1318 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical